Which has the lower trailing P/E, CORT or ICLR?

ICLR has the lower trailing P/E: CORT trades at 290.55 and ICLR at 39.51. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, CORT or ICLR?

Over the past five years, ICLR grew revenue faster — CORT at a 19.35% CAGR versus ICLR at 20.93%.

Is CORT or ICLR more profitable?

CORT runs the higher net margin — CORT at 6.61% versus ICLR at 3.99%.

How have CORT and ICLR total returns compared?

Over the past 10 years, CORT delivered 33.70% and ICLR delivered 8.07% annualized total return. Past performance doesn't predict future results.

Corcept Therapeutics Incorporated (CORT) vs ICON Public Limited Company (ICLR)

A side-by-side comparison of Corcept Therapeutics Incorporated and ICON Public Limited Company across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CORT

Corcept Therapeutics Incorporated

$13.19B

$122.03HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

ICLR

ICON Public Limited Company

$12.89B

$168.33HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — CORT vs ICLR

growth of $100 · dividends reinvested · last 10y

CORT +1754.6% (+33.9%/yr)ICLR +121.1% (+8.3%/yr)CORT compounded faster over this window

Log scale — wide-divergence pair

CORT ICLR

CORT vs ICLR: by the numbers

•CORT is the larger company ($13.19B vs $12.89B market cap).
•ICLR trades at the lower trailing earnings multiple (39.51 vs 290.55 P/E), one valuation lens rather than an overall verdict.
•CORT converts more revenue to profit (6.61% vs 3.99% net margin).
•ICLR grew revenue faster over the past five years (20.93% vs 19.35% CAGR).

Metrics side by side

Valuation

Metric	CORT	ICLR
P/E ratio	290.55	39.51
Forward P/E	N/A	15.90
P/S ratio	15.88	1.56
P/B ratio	18.69	1.37
EV / EBITDA	1483.24	10.94
FCF yield	0.81%	10.44%

Profitability

Metric	CORT	ICLR
Gross margin	98.30%	21.85%
Operating margin	0.77%	10.15%
Net margin	6.61%	3.99%
ROE	7.78%	3.51%
ROIC	0.87%	4.80%

Growth (annualized)

Metric	CORT	ICLR
Revenue CAGR (5Y)	19.35%	20.93%
EPS CAGR (5Y)	0.64%	-14.23%
FCF CAGR (5Y)	-4.40%	22.10%
Total return CAGR (5Y)	43.90%	-8.50%

Frequently asked

Which has the lower trailing P/E, CORT or ICLR?: ICLR has the lower trailing P/E: CORT trades at 290.55 and ICLR at 39.51. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, CORT or ICLR?: Over the past five years, ICLR grew revenue faster — CORT at a 19.35% CAGR versus ICLR at 20.93%.
Is CORT or ICLR more profitable?: CORT runs the higher net margin — CORT at 6.61% versus ICLR at 3.99%.
How have CORT and ICLR total returns compared?: Over the past 10 years, CORT delivered 33.70% and ICLR delivered 8.07% annualized total return. Past performance doesn't predict future results.

Go deeper

Full CORT analysis Full ICLR analysis Interactive comparison tool

Dig into the metrics

Corcept Therapeutics P/E ratio ICON Public P/E ratio Corcept Therapeutics ROE ICON Public ROE Corcept Therapeutics operating margin ICON Public operating margin Corcept Therapeutics revenue growth ICON Public revenue growth Corcept Therapeutics free cash flow ICON Public free cash flow

Corcept Therapeutics & ICON Public appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.